The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Roche has provided an update on Olesoxime and RG7916

    Roche has provided an updateRoche has provided an update on the development of neuroprotective agent Olesoxime and small molecule RG7916, which acts on the SMN2 gene.

    This updates includes information on which trials are currently recruiting, what the eligibility criteria are and how to participate in a trial as well as information on trial design.

    You can also find out more about the methods of actions of each molecule on our clinical trials’ page:

    Please also visit Roche’s clinical trial website.